Merck, Samsung JV Team Up On Biosimilar Meds Manufacturing.net The company, based in Whitehouse Station, N.J., has said it's developing an experimental biosimilar version of rituximab, an antibody-based biologic drug sold under brand names including Rituxan. Samsung Bioepis is a joint venture between Korea's ... |
